Valley Fever Market Research Report- Forecast to 2027

Valley Fever Market Information, by Types of Treatments (Fluconazole, Itraconazole, Voriconazole, Posaconazole, Others) by Site of Infection (Skin, Liver, Bones, Heart, Brain, Membranes That Surround the Brain and Spinal Cord, Others) - Forecast to 2027

ID: MRFR/Pharma/1339-HCR | February 2021 | Region: Global | 80 pages

Valley Fever Market Scenario: 

Valley fever which is also known as coccidioidomycosis, it is a fungal infection with the name Coccidioides fungus. This type of fungus is commonly found in soil and dust of various parts of the world mainly the Americas region. The spores are most expected to appear in wet or warm soil after hefty rain fall. The bacteria are then tired into the air by anything that disturbs the soil, such as wind, construction, and farming. People can then contract valley fever by breathing in these tiny, airborne fungal bacteria. Globally the market for Valley Fever market is expected to grow at the rate of about XX% from 2016 to 2022. 

Valley Fever Market, by types of treatment  

Study objectives of the Valley Fever Market:

  • To provide detailed analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the Valley Fever market

  • To provide insights about factors affecting the market growth

  • To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to the main geography and its countries - North America, Europe, Middle East & Africa.

  • To provide country level analysis of the market with respect to the current market size and future prospective

  • To provide country level analysis of the market for segments by types of treatment, by site of infection, and its sub-segments.

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the market.

Intended Audience

  • Valley Fever Drugs manufacturers & Suppliers

  • Anti-fungal drug manufacturing companies

  • Pharmaceutical and biotechnology companies

  • Hospitals and laboratories

  • Research institutes

Key Finding

  • The North American market is expected to reach $XX billion by 2022.

  • Itraconazole medication holds the largest share of XX% of the Valley Fever market.

  • American market holds the largest market share of XX% of Valley Fever and is expected to reach $XX billion by the end of forecast period.

  • Europe is expected to be the steadily growing market at a CAGR of XX%


Valley Fever market has been segmented on the basis of site of infection which comprises of skin, liver, bones, heart, brain, membranes that surround the brain and spinal cord and others. On the basis of treatments the market is segmented into fluconazole, itraconazole, voriconazole, posaconazole and others

Regional Analysis of the Market:              

Globally Americas is the largest market for Valley Fever. Europe is expected to be the second-largest market

Key Players for the Market:
Some of the key players in this valley fever market are: 

  • Novartis

  • Anacor Pharmaceuticals

  • Johnson and Johnson

  • Valeant Pharmaceutical

  • Bristol Meyer Squibb

  • GlaxoSmithKline Pharmaceuticals Limited

  • Galderma S.A.

  • Pfizer Inc.

The report for Valley Fever market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions

Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant value
  CAGR   2020–2027: substantial CAGR
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Types of Treatments, Site of Infection
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Novartis, Anacor Pharmaceuticals, Johnson and Johnson, Valeant Pharmaceutical, Bristol Meyer Squibb, GlaxoSmithKline Pharmaceuticals Limited, Galderma S.A., Pfizer Inc
  Key Market Opportunities   New product developments
  Key Market Drivers

  • R&D activities for the innovation of newer drugs
  • Developing and manufacturing innovative products

  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The site of infection in the valley fever includes fluconazole, voriconazole, posaconazole and others itraconazole,

    Treatments discussed in the valley fever market are itraconazole, voriconazole, posaconazole fluconazole, and others.

    The valley fever market has players like Anacor Pharmaceuticals, Novartis, , Valeant Pharmaceutical, Johnson and Johnson, GlaxoSmithKline Pharmaceuticals Limited, Galderma S.A., Pfizer Inc., Bristol Meyer Squibb, and others.

    The Americas would hold the key of the valley fever market.

    The treatment type segment would be dominated by Itraconazole.

    1 Introduction

    1.1 Definition

    1.2 Scope of Study

    1.3 Research Objective

    1.4 Assumptions & Limitations

    1.5 Market Structure
    2 Research Methodology

    2.1 Research Process

    2.2 Primary Research

    2.3 Secondary Research
    3 Market Dynamics

    3.1 Drivers

    3.2 Restraints

    3.3 Opportunities

    3.4 Challenges

    3.5 Macroeconomic Indicators
    4 Market Factor Analysis

    4.1 Porter’s five forces model

    4.1.1 Bargaining Power of suppliers

    4.1.2 Bargaining Power of Customer

    4.1.3 Intensity of Competitor’s

    4.1.4 Threat of New Entrants

    5 Global Valley Fever Market, by Types of treatment

    5.1 Introduction

    5.1.1 Fluconazole

    5.1.2 Itraconazole

    5.1.3 Voriconazole

    5.1.4 Posaconazole

    5.1.5 Others
    6 Global Valley Fever Market, by site of infection

    6.1 Introduction

    6.1.1 Skin

    6.1.2 Liver

    6.1.3 Heart

    6.1.4 Bones

    6.1.5 Others
    7 Global Valley Fever Market, by regions

    7.1 Introduction

    7.1.1 North America US Canada

    7.1.2 Europe Germany France UK Italy Spain Rest of Europe

    7.1.3 Asia Pacific Japan China India South Korea Rest of Asia Pacific

    7.1.4 Middle East & Africa
    8 Company Landscape

    8.1 Introduction

    8.1.1 Mergers Acquisitions

    8.1.2 Collaborations

    8.1.3 Release/New Product Launches
    9 Company Profile

    9.1 Novartis

    9.1.1 Company Overview

    9.1.2 Product/Business Segment Overview

    9.1.3 Financials

    9.1.4 Key Developments

    9.2 Anacor Pharmaceuticals

    9.2.1 Overview

    9.2.2 Product/Business Segment Overview

    9.2.3 Financials

    9.2.4 Key Developments

    9.3 Johnson and Johnson

    9.3.1 Overview

    9.3.2 Product/Business Segment Overview

    9.3.3 Financials

    9.3.4 Key Developments

    9.4 Bristol Meyer Squibb

    9.4.1 Overview

    9.4.2 Product/Business Segment Overview

    9.4.3 Financials

    9.4.4 Key Developments

    9.5 Valeant Pharmaceutical

    9.5.1 Overview

    9.5.2 Product/Business Segment Overview

    9.5.3 Financials

    9.5.4 Key Developments
    10 Appendix